Greene D A, Lattimer S A
Diabetes. 1984 Aug;33(8):712-6. doi: 10.2337/diab.33.8.712.
The small, but statistically significant, improvement in nerve conduction after treatment of diabetic patients with the aldose reductase inhibitor, sorbinil, suggests that increased polyol (sorbitol) pathway activity may contribute to diabetic nerve conduction slowing. Although classically viewed solely in terms of sorbitol-induced osmotic swelling, polyol pathway inhibition is now speculated to influence a concomitant myo-inositol-mediated alteration in nerve sodium-potassium ATPase activity in diabetic nerve. Therefore, we directly examined the effect of sorbinil treatment on sodium-potassium ATPase activity in crude homogenates of sciatic nerve from streptozotocin-diabetic and non-diabetic rats. We demonstrate that sorbinil treatment, which preserves normal nerve myo-inositol content, prevents the fall in nerve sodium-potassium ATPase activity that has been linked to conduction slowing in the diabetic rat.
用醛糖还原酶抑制剂索比尼尔治疗糖尿病患者后，神经传导虽有小幅改善，但具有统计学意义，这表明多元醇（山梨醇）途径活性增加可能导致糖尿病神经传导减慢。尽管传统上仅从山梨醇诱导的渗透性肿胀角度来看待，但现在推测多元醇途径抑制会影响糖尿病神经中伴随的肌醇介导的神经钠钾ATP酶活性改变。因此，我们直接研究了索比尼尔治疗对链脲佐菌素诱导的糖尿病大鼠和非糖尿病大鼠坐骨神经粗匀浆中钠钾ATP酶活性的影响。我们证明，索比尼尔治疗可维持正常神经肌醇含量，防止与糖尿病大鼠传导减慢相关的神经钠钾ATP酶活性下降。
